BeSmooth Study, Investigating the BeSmooth Peripheral Stent System for the Treatment of Iliac Lesions

Peripheral Arterial Disease Clinical Trial

— BeSmooth  

Official title:

BeSmooth Study, a Physician-initiated PMCF Trial Investigating the BeSmooth Peripheral Stent System for the Treatment of Iliac Lesions

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02690051
• Other study ID #: FMRP-140702
• Status: Completed
• Phase: Phase 4
• First received: February 2, 2016
• Last updated: January 11, 2017
• Start date: October 2014
• Est. completion date: December 2016

Study information

• Verified date: February 2016
• Source: Flanders Medical Research Program
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

A Physician initiated PMCF Trial Investigating the BeSmooth Peripheral Stent System for the treatment of Iliac Lesions.

The objective of this clinical investigation is to evaluate the long-term safety and efficacy of the BeSmooth Peripheral Stent System in clinical settings post CE-certification when used according to the indications of the IFU.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 70
• Est. completion date: December 2016
• Est. primary completion date: December 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Corresponding to the CE-mark indications/contra-indications and according to the current medical guidelines for minimally invasive peripheral interventions.

2. Patient presenting with a stenotic or occlusive lesion at the iliac arteries suitable for stenting (on indication for primary stenting, based on the discretion of the investigator)

3. Patient presenting a score from 2 to 5 following Rutherford classification

4. Patient is willing to comply with specified follow-up evaluations at the specified times for the duration of the study

5. Patient is >18 years old

6. Patient (or their legal representative) understands the nature of the procedure and provides written informed consent, prior to enrolment in the study

7. Patient is eligible for treatment with the BeGraft Peripheral Stent Graft System (Bentley InnoMed)

8. The target lesion is either a modified TASC-II class A, B, C or D lesion with one of the listed specifications:

• Type A lesions

• Unilateral or bilateral stenoses of the Common Iliac Artery

• Unilateral or bilateral single short (=3 cm) stenosis of the External Iliac Artery

• Type B lesions

• Unilateral Common Iliac Artery occlusion

• Single or multiple stenosis totaling 3-10 cm involving the External Iliac Artery not extending into the Common Femoral Artery

• Unilateral External Iliac Artery occlusion not involving the origins of Internal Iliac Artery or Common Iliac Artery

• Type C lesions

• Bilateral Common Iliac Artery occlusions

• Bilateral External Iliac Artery stenoses 3-10 cm long not extending into the Common Femoral Artery

9. The target lesion has angiographic evidence of stenosis or restenosis > 50% or occlusion which can be passed with standard guidewire manipulation

10. There is angiographic evidence of a patent Common an Deep Femoral Artery

Exclusion Criteria:

1. PTA is technically not possible (not feasible to access the lesion or a defect with the guidewire or balloon catheter)

2. Presence of an aneurysm immediately adjacent to the site of stent implantation

3. Stenosis distal to the site of stent implantation

4. Lesions in or adjacent to essential collaterals(s)

5. Lesions in locations subject to external compression

6. Heavily calcified lesions resistant to PTA

7. Patients with diffuse distal disease resulting in poor stent outflow

8. Patients with a history of coagulation disorders

9. Patients with aspirin allergy or bleeding complications and patients unable or unwilling to tolerate anticoagulant/antiplatelet therapy and/or non-responders to anticoagulant/antiplatelet therapy

10. Fresh thrombus formation

11. Patients with known hypersensitivity to the stent material(L605)

12. The target lesion is either a modified TASC-II class B or D lesion with aortic or common femoral lesion involvement:

• Type B lesions

-Short (=3 cm) stenosis of infrarenal aorta

• Type C lesions

• Unilateral External Iliac Artery stenosis extending into the Common Femoral Artery

• Unilateral External Iliac Artery occlusion that involves the origins of the Internal Iliac and/or Common Femoral Artery

• Heavily calcified unilateral External Iliac Artery occlusion with or without involvement of origins of the Internal Iliac and/or Common Femoral Artery

• Type D lesions

• Infra-renal aortoiliac occlusion

• Iliac stenoses in patients with an Abdominal Aortic Aneurysm (AAA) requiring treatment and not amenable to endograft placement or other lesions requiring open aortic or iliac surgery

• Diffuse multiple stenoses involving the unilateral Common Iliac, External Iliac and Common Femoral Artery

• Unilateral occlusions of both Common Iliac and External Iliac Artery

• Diffuse disease involving the aorta and both iliac arteries requiring treatment

• Bilateral occlusions of the External Iliac Artery

13. Previously implanted stent(s) at the same lesion site

14. Reference segment diameter is not suitable for the available stent design

15. Untreatable lesion located at the distal outflow arteries

16. Use of alternative therapy (e.g. atherectomy, cutting balloon, laser, radiation therapy) as part of the index procedure

17. Patients refusing treatment

18. Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated

19. Patients who exhibit persistent acute intraluminal thrombus of the proposed lesion site

20. Perforation at the angioplasty site evidenced by extravasation of contrast medium

21. Patients with a history of prior life-threatening contrast medium reaction

22. Patients with uncorrected bleeding disorders

23. Female patient with child bearing potential not taking adequate contraceptives or currently breastfeeding

24. Life expectancy of less than twelve months

25. Any planned surgical intervention/procedure within 30 days of the study procedure

26. Any patient considered to be hemodynamically unstable at onset of procedure

27. Patient is currently participating in another investigational drug or device study that has not completed the entire follow up period

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Peripheral Arterial Disease
• Peripheral Vascular Diseases

Intervention

Device:
• BeSmooth peripheral stent
patients treated with the BeSmooth Peripheral Stent System

Locations

Country	Name	City	State
Belgium	OLV Hospital	Aalst
Belgium	Imelda Hospital Bonheiden	Bonheiden
Belgium	AZ Sint-Blasius	Dendermonde
Belgium	Heilig Hart Hospital	Tienen

Sponsors (1)

Lead Sponsor	Collaborator
Flanders Medical Research Program

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary Patency at 12 months	defined as a target lesion without a hemodynamically significant stenosis on duplex ultrasound (>50%, systolic velocity ratio no greater than 2.4) and without Target Lesion Revascularization (TLR) within 12 months.	12 months	No
Secondary	Primary Patency at 1 & 6 month	Patients that present without a hemodynamically significant stenosis at the target area on duplex ultrasound (>50%, systolic velocity ratio no greater than 2.4) and without prior TLR are defined as being primary patent at the given follow-up.	1 and 6 months	No
Secondary	Stent Occlusion Rate at 1,6 and 12-month follow-up	100% (re)occlusion rate within the study stent	up to 12 months	No
Secondary	ABI at 1,6 and 12-month follow-up, compared with baseline	Ankle-Brachial index measurements at 1,6 and 12-month FU visit, compared with measurements at baseline (pre operatively)	up to 12 months	No
Secondary	Amputation rate at 1,6 and 12-month follow-up	Amputation rate at 1-, 6- and 12-month follow-up, defined as any amputation above the knee.	up to 12 months	No
Secondary	Performance success rate at baseline, defined as restoration of blood flow	Device success, restoration of blood flow during index procedure	during the index study procedure	No
Secondary	In-stent restenosis rate	restenosis rate within the study stent	up to 12 months	No
Secondary	Freedom from Target Lesion Revascularization	Freedom from Target Lesion Revascularization (TLR), defined as freedom from a repeat intervention to maintain or re-establish patency within the region of the treated arterial vessel plus 5mm proximal and distal to the treated lesion edge.	up to 12 months	No
Secondary	Serious Adverse Events	Serious Adverse Events (SAEs), defined according to ISO 14155:2011 as any clinical event that is fatal, life-threatening, or judged to be severe by the investigator; resulted in persistent or significant disability; necessitated surgical or percutaneous intervention; or required prolonged hospitalization.	up to 12 months	No
Secondary	Technical success	The ability to achieve final residual angiographic stenosis no greater than 30%	during the index study procedure	No
Secondary	Clinical success at follow-up is defined as an improvement of Rutherford Classification at 1-,6- and 12-month follow-up	Clinical success at follow-up is defined as an improvement of Rutherford classification at 1-, 6- and 12-month follow-up of one class or more as compared to the pre-procedure Rutherford classification	up to 12 months	No